Registry and cohort study of pulmonary vascular disease

National Registry and Cohort Study of Pulmonary Vascular Disease

This study looks at patients with pulmonary hypertension to understand their causes, treatments, and outcomes while building a system to collect and share this information for better future care.

Quick facts

• Study type: Observational
• Enrollment: 1000 (estimated)
• Sex: All
• Sponsor: Nanjing First Hospital, Nanjing Medical University (other)
• Locations: 13 sites (Guangzhou, Guangdong and 12 other locations)
• Trial ID: NCT05368467 on ClinicalTrials.gov

What this trial studies

This observational, multicenter, prospective cohort study focuses on patients with pulmonary hypertension (PH). It aims to evaluate the causes, clinical characteristics, treatment options, and outcomes of PH patients while establishing a registration system and database for PH in China. The study will also create a web-based data acquisition system and a multicenter clinical research platform to enhance future research and health policy related to PH.

Who should consider this trial

Good fit: Ideal candidates include newly diagnosed or previously diagnosed patients with pulmonary hypertension who have documented mean pulmonary arterial pressure greater than 20 mm Hg.

Not a fit: Patients who do not meet the hemodynamic criteria for pulmonary hypertension or lack prior documentation of these criteria will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved understanding and management of pulmonary hypertension, ultimately enhancing patient outcomes.

How similar studies have performed: Other studies focusing on pulmonary hypertension have shown success in improving understanding and treatment, making this approach both relevant and potentially impactful.

Eligibility criteria

Inclusion Criteria:

* Newly diagnosed or previously diagnosed patients with PH.
* Documentation of mean pulmonary arterial pressure (mPAP) \>20 mm Hg by right heart catheterization, performed at any time prior to study enrollment.

Exclusion Criteria:

* Have not had documentation of hemodynamic criteria for PH by right heart catheterization at some time preceding study entry and following development of symptoms associated with PH.
* Do not meet the required hemodynamic criteria for entry into the study.

Where this trial is running

Guangzhou, Guangdong and 12 other locations

• Guangdong Provincial Peoples Hospital — Guangzhou, Guangdong, China (RECRUITING)
• Nanjing First Hospital — Nanjing, Jiangsu, China (RECRUITING)
• General Hospital of Tianjin Medical University — Tianjin, Tianjin Municipality, China (RECRUITING)
• Beijing Anzhen Hospital of Capital Medical University — Beijing, China (RECRUITING)
• China-japan Friendship Hospital — Beijing, China (RECRUITING)
• Xiangya Second Hospital, Central South University — Changsha, China (RECRUITING)
• West China Hospital, Sichuan University — Chendu, China (RECRUITING)
• Nanjing Drum Tower Hospital — Nanjing, China (RECRUITING)
• General Hospital of Northen Theater of Command — Shenyang, China (RECRUITING)
• Tongji Hospital, Huazhong University of Science and Technology — Wuhan, China (RECRUITING)
• Zhongnan Hospital of Wuhan University — Wuhan, China (RECRUITING)
• First Affiliated Hospital of Xi'An Jiaotong University — Xi'an, China (RECRUITING)
• First Hospital of Zhengzhou University — Zhengzhou, China (RECRUITING)

Study contacts

• Study coordinator: Shao-Liang Chen, MD, PhD

Conditions: Pulmonary Arterial Hypertension